Australian job vacancies hit highest level since 2024
Australian job vacancies rose 2.7% to February, reaching 337,900 openings, according to the Australian Bureau of Statistics.
Australian job vacancies rose 2.7% to February, reaching 337,900 openings, according to the Australian Bureau of Statistics.
Pathkey.AI (ASX:PKY) has executed a strategic services agreement with Imunexus Therapeutics.
X2M Connect (ASX:X2M) has formalised a smart community agreement with Resi Ventures.
Novo Nordisk (NYSE:NVO) has intensified its rivalry with Eli Lilly (NYSE:LLY), releasing a provocative cross-trial analysis that claims its experimental Wegovy pill is both more effective and better tolerated than Lilly’s recently approved obesity tablet, Foundayo.
ECARX Holdings (NASDAQ:ECX) achieved a historic financial turning point in the final months of 2025, reporting its first-ever quarterly net income as a public company alongside a surge in shipments for its flagship automotive computing platforms.
SoFi has introduced a new enterprise platform called Big Business Banking aimed at combining traditional finance with digital asset infrastructure.
Tesla (NASDAQ:TSLA) reported first-quarter delivery numbers that fell short of Wall Street expectations, raising fresh concerns about a widening gap between the electric vehicle maker's manufacturing pace and global consumer appetite.
Wallet in Telegram, a third-party wallet built inside Telegram, has introduced perpetual futures trading through a new integration with Lighter, a decentralised exchange focused on derivatives.
Innovative Aerosystems (NASDAQ:ISSC) has reached an agreement with Honeywell International (NASDAQ:HON) to acquire key assets and intellectual property for select legacy avionics lines, a move that deepens the company’s reach into the global general aviation market.
Merck (NYSE:MRK) has secured a landmark regulatory approval in the European Union for its blockbuster immunotherapy Keytruda, marking the region’s first PD-1 inhibitor authorized to treat a particularly aggressive form of ovarian cancer.
GET YOUR GRAFA EDGE NOW
We'll switch on a 30-day Edge trial as a welcome gift
Got a second for a cookie? 🍪Essential cookies keep Grafa running smoothly. A few optional ones help us see what's working so we can make it better. You're in control — change your mind any time. Cookie policy · Privacy policy
